Ground Swell Capital’s Filana Therapeutics FLNA Stock Holding History

Ground Swell Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,985	Closed	-$30.7K	–	220
2025 Q2	$30.7K	Buy	+16,985	New	+$30.2K	0.05%	81

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ground Swell Capital's FLNA Position: Q3 2025 in Review

Ground Swell Capital sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 16,985 shares — an estimated $30.7K sold.

Ground Swell Capital first reported a position in FLNA in Q2 2025 and held it in 1 quarter. The position peaked at $30.7K in Q2 2025. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

Ground Swell Capital reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
Ground Swell Capital sold 16,985 Filana Therapeutics shares in Q3 2025, an estimated $30.7K.
Ground Swell Capital first reported a position in Filana Therapeutics in Q2 2025 and held it in 1 quarter.
Ground Swell Capital's Filana Therapeutics position peaked at $30.7K in Q2 2025.
103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.